Bio-Path Holdings ((BPTH)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bio-Path Holdings is conducting a Phase I/Ib clinical study titled ‘A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors.’ The study aims to determine the safety and maximum tolerated dose of BP1001-A, a novel treatment for advanced solid tumors, and assess its efficacy in combination with paclitaxel. This research is significant as it explores new therapeutic options for challenging cancer types.
The intervention being tested is BP1001-A, a liposomal Grb2 antisense oligonucleotide. It is administered intravenously and designed to inhibit cancer cell growth by targeting specific genetic pathways. The study also examines BP1001-A in combination with the chemotherapy drug paclitaxel.
The study follows a non-randomized, sequential intervention model with no masking, focusing on treatment. It consists of two phases: dose escalation to find the maximum tolerated dose of BP1001-A, followed by dose expansion to evaluate its combined effect with paclitaxel.
The study began on December 10, 2019, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on March 6, 2025. These dates are crucial for tracking the study’s progress and potential market introduction.
This clinical update could positively influence Bio-Path Holdings’ stock performance, as successful results may enhance investor confidence and market position. The study’s outcome could also impact the competitive landscape, particularly in the oncology sector, where innovative treatments are highly sought after.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.